Best Biologics / mAb CDMOs in India
· updated as new inspection, certificate, and trial data enters the platform
15
CDMOs tracked
6
Fully scored
4
With FDA records
13
FDA inspections
14
EMA/MHRA GMP certs
2
Warning letters
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 5 NAI (no action), 7 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: India (8), UNITED KINGDOM (8), United States (4), INDIA (4), Canada (1).
Last updated 2026-08-16. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.6 | 95.7 | 5 insp · 13 GMP | — | 0 programs |
| 2 |
SG
Syngene International
Bengaluru, India
|
79.7 | 95.9 | 2 insp · 0 GMP | — | 0 programs |
| 3 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 4 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 5 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 6 |
IC
INCOG BioPharma Services
Fishers, IN
|
56.5 | — | — | — | 0 programs |
| — |
Sun Pharmaceutical Industries Ltd.
Mumbai, India
|
Profiled | — | 5 insp · 0 GMP | — | 0 programs |
| — |
Biological E. Limited (BioE)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Aurobindo Pharma (Sterile Injectables Division)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
BE Biosol (formerly SGI Pharma / Biological E, Samirpet)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Eli Lilly (Internal Manufacturing — Lebanon, IN)
Indianapolis, IN
|
Profiled | — | — | — | 0 programs |
| — |
Laurus Labs
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Dr. Reddy's Laboratories
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Enzene Biosciences
Pune, India
|
Profiled | — | — | — | 0 programs |
| — |
Anthem Biosciences
Bengaluru, India
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
How do Indian CDMOs compare to Chinese and Korean alternatives on regulatory posture?
Indian CDMOs have historically led Asian peers in FDA inspection density — the FDA maintains a large inspection presence in India and Indian pharmaceutical exports to the US are among the highest globally. That translates to Indian CDMOs typically holding more FDA inspections on record than Chinese or Korean counterparts of comparable size. That said, inspection density is not the same as inspection outcome — the Signal Score's Quality Compliance pillar weights the classification (NAI/VAI/OAI), not just the count. Sponsors comparing Asian CDMOs should focus on the specific facility's inspection outcome record, not the country-aggregate; individual profile pages surface facility-level detail.
Which Indian CDMOs handle biologics and advanced therapy modalities?
India's CDMO base has traditionally been strongest in small molecules and oral solid dosage forms, but the biologics and advanced-therapy footprint has grown substantially. Notable capabilities exist across mAb manufacturing, biosimilar production, and increasingly viral vector + cell therapy. Cross-reference with modality pages to filter Indian CDMOs by capability class: biologics, mRNA, cell therapy, or the gene therapy umbrella. Individual CDMO profile pages surface the specific modality capabilities on file.
US and EU regulatory considerations for India-manufactured drug supply
Indian CDMOs supplying US markets need active FDA registrations and pre-approval inspection posture; the FDA has been publicly focused on Indian generic pharmaceutical quality for years, and inspection outcomes there materially affect commercial supply eligibility. EU supply requires EMA GMP certification with an EU-based Qualified Person for batch release, which for Indian-manufactured material requires either an EU-based CDMO partner for release or an in-house EU QP arrangement. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Indian CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Piramal Pharma Solutions, Syngene International, Simtra BioPharma Solutions. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 4 Biologics / mAb CDMOs with FDA inspection records and 14 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities